Article(id=1326652289231729022, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652288703246717, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.08.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1744905600000, receivedDateStr=2025-04-18, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228153759, onlineDateStr=2026-11-09, pubDate=1754755200000, pubDateStr=2025-08-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228153759, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228153759, creator=13701087609, updateTime=1794228153759, updator=13701087609, issue=Issue{id=1326652288703246717, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='8', pageStart='737', pageEnd='868', issueExtLink='null', onlineDate='null', pubDate='1754755200000', pubDateStr='2025-08-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228153634, creator='13701087609', updateTime=1794272975026, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840283779675018, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652288703246717, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840283783869323, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652288703246717, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=737, endPage=743, ext={EN=ArticleExt(id=1326652289403695487, articleId=1326652289231729022, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Advances of immune checkpiont inhibitor-related cutaneous adverse events, columnId=null, journalTitle=World Clinical Drug, columnName=null, runingTitle=null, highlight=null, articleAbstract=

Immune checkpoint inhibitors(ICIs), as revolutionary drugs in cancer therapy, play an anti-tumor role by blocking immune checkpoint signals and enhancing the body's immune response to tumor cells, but also cause a series of immune-related adverse events(irAEs). Cutaneous irAEs(cirAEs) are one of the most common types. This paper reviewed the mechanism, clinical manifestations, treatment and prognosis of cirAEs, and briefly elaborated the relationship between cirAEs and well-known drug eruptions, aiming to increase the awareness of medical professionals about ICIs-related cirAEs and provide guidance for clinical treatment.

, authors=Lili MA, Ruilian LIN, Jia CHEN*, authorsList=Lili MA, Ruilian LIN, Jia CHEN, authorCompany=null, correspAuthors=Jia CHEN, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326652289735045504, articleId=1326652289231729022, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=免疫检查点抑制剂皮肤相关不良反应的研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)作为恶性肿瘤治疗的突破性药物,通过阻断免疫检查点信号,增强机体对肿瘤细胞的免疫反应从而发挥抗肿瘤作用,但同时也会导致一系列免疫相关不良事件(immune-related adverse events,irAEs),其中皮肤irAEs(cutaneous irAEs,cirAEs)是常见类型之一。该文综述ICIs引起cirAEs的机制、临床表现、治疗及预后,并简要阐述cirAEs与已知药疹的关联,旨在提高医疗专业人员对ICIs相关cirAEs的认识,并为临床治疗提供指导。

, authors=马丽丽, 林瑞莲, 陈佳*, authorsList=马丽丽, 林瑞莲, 陈佳, authorCompany=null, correspAuthors=陈佳, authorNote=

马丽丽,住院医师,研究方向:皮肤与性病学、自身免疫性疾病。

, correspAuthorsNote=
陈佳,主任医师,研究方向:皮肤病理、自身免疫性疾病。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=fGrybQXBWYNf0kMgorgT3g==, magXml=72/o0sk1IH2U4guP/FwbHw==, pdfUrl=null, pdf=+MVSF7oUFMXkDmnuL4fOPg==, pdfFileSize=1012774, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=VdBSa+5iDPEBTsNvJ4FkDw==, mapNumber=null, fund=null)}, authors=[Author(id=1326652291597316485, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652291672813959, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291597316485, language=EN, stringName=Lili MA, firstName=Lili, middleName=null, lastName=MA, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652291727339912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291597316485, language=CN, stringName=马丽丽, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=同济大学附属皮肤病医院风湿免疫科,上海 200443, bio={"content":"

马丽丽,住院医师,研究方向:皮肤与性病学、自身免疫性疾病。

"}, bioImg=null, bioContent=

马丽丽,住院医师,研究方向:皮肤与性病学、自身免疫性疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652289953149313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, xref=null, ext=[AuthorCompanyExt(id=1326652289961537922, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China), AuthorCompanyExt(id=1326652289969926531, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=同济大学附属皮肤病医院风湿免疫科,上海 200443)])]), Author(id=1326652291786060170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652291857363340, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291786060170, language=EN, stringName=Ruilian LIN, firstName=Ruilian, middleName=null, lastName=LIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652291916083597, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291786060170, language=CN, stringName=林瑞莲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=同济大学附属皮肤病医院风湿免疫科,上海 200443, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652289953149313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, xref=null, ext=[AuthorCompanyExt(id=1326652289961537922, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China), AuthorCompanyExt(id=1326652289969926531, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=同济大学附属皮肤病医院风湿免疫科,上海 200443)])]), Author(id=1326652291974803855, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652292037718417, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291974803855, language=EN, stringName=Jia CHEN, firstName=Jia, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652292096438674, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291974803855, language=CN, stringName=陈佳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=同济大学附属皮肤病医院风湿免疫科,上海 200443, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652289953149313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, xref=null, ext=[AuthorCompanyExt(id=1326652289961537922, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China), AuthorCompanyExt(id=1326652289969926531, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=同济大学附属皮肤病医院风湿免疫科,上海 200443)])])], keywords=[Keyword(id=1326652292197101971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, language=EN, orderNo=1, keyword=immune-related adverse events), Keyword(id=1326652292255822228, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, language=EN, orderNo=2, keyword=skin immune-related adverse events), Keyword(id=1326652292310348181, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, language=EN, orderNo=3, keyword=immune checkpoint inhibitors), Keyword(id=1326652292373262742, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, language=CN, orderNo=1, keyword=免疫相关不良事件), Keyword(id=1326652292448760215, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, language=CN, orderNo=2, keyword=皮肤免疫相关不良事件), Keyword(id=1326652292511674776, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, language=CN, orderNo=3, keyword=免疫检查点抑制剂)], refs=[Reference(id=1326652292587172249, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=BARRON CC, STEFANOVA I, CHA Y, et al. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review[J]. J Immunother Cancer, 2023, 11(8): e006500., articleTitle=null, refAbstract=null), Reference(id=1326652292645892506, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=GEISLER AN, PHILLIPS GS, BARRIOS DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events[J].J Am Acad Dermatol, 2020, 83(5): 1255-1268., articleTitle=null, refAbstract=null), Reference(id=1326652292704612763, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=WONGVIBULSIN S, PAHALYANTS V, KALINICH M,et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis[J]. J Am Acad Dermatol, 2022, 86(3): 563-572., articleTitle=null, refAbstract=null), Reference(id=1326652292763333020, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=LYUBCHENKO T, LEUNG DYM, GOLEVA E. Why are immune adverse events so common with checkpoint inhibitor therapy?[J]. Ann Allergy Asthma Immunol, 2021, 126(6):608-610., articleTitle=null, refAbstract=null), Reference(id=1326652292826247581, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=PETITPREZ F, DE REYNIES A, KEUNG EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma[J]. Nature, 2020, 577(7791): 556-560., articleTitle=null, refAbstract=null), Reference(id=1326652292901745054, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=KANG JH, BLUESTONE JA, YOUNG A. Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines[J]. Trends Immunol, 2021, 42(4): 293-311., articleTitle=null, refAbstract=null), Reference(id=1326652292960465311, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=CHAM J, ZHANG L, KWEK S, et al. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies[J].J Immunother Cancer, 2020, 8(1): e000368., articleTitle=null, refAbstract=null), Reference(id=1326652293031768480, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=TENG YS, YU S. Molecular mechanisms of cutaneous immune-related adverse events(irAEs) induced by immune checkpoint inhibitors[J]. Curr Oncol, 2023, 30(7): 6805-6819., articleTitle=null, refAbstract=null), Reference(id=1326652293107265953, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=NISHIMURA K, KONISHI T, OCHI T, et al. CD21lo B Cells could be a potential predictor of immune-related adverse events in renal cell carcinoma[J]. J Pers Med, 2022, 12(6):888., articleTitle=null, refAbstract=null), Reference(id=1326652293174374818, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=GU SL, MAIER T, MOY AP, et al. IL12/23 blockade with ustekinumab as a treatment for immune-related cutaneous adverse events[J]. Pharmaceuticals(Basel), 2023, 16(11):1548., articleTitle=null, refAbstract=null), Reference(id=1326652293254066595, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=SHIPMAN WD, SINGH K, COHEN JM, et al. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin(IL)-4 and IL-13 expression and responds to dupilumab treatment[J]. Br J Dermatol, 2023,189(3): 339-341., articleTitle=null, refAbstract=null), Reference(id=1326652293325369764, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=OKIYAMA N, TANAKA R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors[J].Allergol Int, 2022, 71(2): 169-178., articleTitle=null, refAbstract=null), Reference(id=1326652293400867237, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=YIN Q, WU L, HAN L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review[J]. Front Immunol, 2023, 14: 1167975., articleTitle=null, refAbstract=null), Reference(id=1326652293476364710, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=STARACE M, RAPPARINI L, CEDIRIAN S, et al.Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience[J].Support Care Cancer, 2024, 32(3): 200., articleTitle=null, refAbstract=null), Reference(id=1326652293551862183, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=ALMODOVAR CRUZ GE, KAUNITZ G, STEIN JE, et al.Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD-1 therapy resemble acute graft versus host disease more than lichen planus[J]. J Cutan Pathol, 2022, 49(8): 701-708., articleTitle=null, refAbstract=null), Reference(id=1326652293618971048, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=BROWN AM, MASTERSON W, LO J, et al. Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: a review[J]. Dermatitis, 2023,34(3): 201-208., articleTitle=null, refAbstract=null), Reference(id=1326652293681885609, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=MUNTYANU A, NETCHIPOROUK E, GERSTEIN W, et al. Cutaneous immune-related adverse events(irAEs) to Immune checkpoint inhibitors: a dermatology perspective on management[J]. J Cutan Med Surg, 2021, 25(1): 59-76., articleTitle=null, refAbstract=null), Reference(id=1326652293744800170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=SUN XJ, MEI XL, LIU Y. Exacerbation of psoriasis induced by nivolumab in a patient with stage Ⅲc gastric adenocarcinoma: a case report and literature review[J]. J Transl Autoimmun, 2023, 6: 100193., articleTitle=null, refAbstract=null), Reference(id=1326652293807714731, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=POPA LG, GIURCANEANU C, PORTELLI MG, et al.Perspectives on psoriasiform adverse events from immune checkpoint inhibitors: lessons learned from our practice[J].Medicina(Kaunas), 2024, 60(3): 373., articleTitle=null, refAbstract=null), Reference(id=1326652293895795116, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=PACH JJ, MBONU N, BHULLAR S, et al. Immune checkpoint inhibitor-induced psoriasis: diagnosis,management, and a review of cases[J]. Dermatol Clin, 2024,42(3): 481-493., articleTitle=null, refAbstract=null), Reference(id=1326652293967098285, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=Schaberg KB, Novoa RA, Wakelee HA, et al.Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy[J]. J Cutan Pathol, 2016, 43(4): 339-346., articleTitle=null, refAbstract=null), Reference(id=1326652294034207150, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=TETZLAFF MT, NAGARAJAN P, CHON S, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features[J]. Am J Dermatopathol, 2017, 39(2): 121-129., articleTitle=null, refAbstract=null), Reference(id=1326652294097121711, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=FIXSEN E, PATEL J, SELIM MA, et al. Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine[J]. Oncologist, 2019, 24(3):e103-e105., articleTitle=null, refAbstract=null), Reference(id=1326652294176813488, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=CARBONE ML, CAPONE A, GUERCIO M, et al. Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy[J]. Front Immunol, 2023, 14: 1197630., articleTitle=null, refAbstract=null), Reference(id=1326652294243922353, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=RAO H, GUO Z, WEN XJ, et al. Case report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data[J]. Front Oncol,2023, 12: 1099108., articleTitle=null, refAbstract=null), Reference(id=1326652294315225522, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=LOMMERTS JE, BEKKENK MW, LUITEN RM. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion[J]. Expert Opin Drug Saf, 2021,20(8): 883-888., articleTitle=null, refAbstract=null), Reference(id=1326652294386528691, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=BHARDWAJ M, CHIU MN, PILKHWAL SAH S. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance[J].Cutan Ocul Toxicol, 2022, 41(1): 73-90., articleTitle=null, refAbstract=null), Reference(id=1326652296072638900, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=TAN HW, CHEN XB, CHEN Y, et al. Immune checkpoint inhibitor-associated bullous pemphigoid: A retrospective and real-world study based on the United States Food and Drug Administration adverse event reporting system[J]. J Dermatol, 2025, 52(2): 309-316., articleTitle=null, refAbstract=null), Reference(id=1326652296143942069, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=NAIDOO J, SCHINDLER K, QUERFELD C, et al.Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1[J]. Cancer Immunol Res, 2016, 4(5): 383-389., articleTitle=null, refAbstract=null), Reference(id=1326652296219439542, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=ASDOURIAN MS, SHAH N, JACOBY TV, et al. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review[J]. J Am Med Assoc Dermatol, 2022, 158(8): 933-941., articleTitle=null, refAbstract=null), Reference(id=1326652296303325623, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=TERRIER B, HUMBERT S, PRETA LH, et al. Risk of scleroderma according to the type of immune checkpoint inhibitors[J]. Autoimmun Rev, 2020, 19(8): 102596., articleTitle=null, refAbstract=null), Reference(id=1326652296383017400, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=PAI HL, LIU CY, YEH MH. Scleroderma-like lesions in a patient undergoing combined pembrolizumab and routine chemotherapy: a case report and literature review[J].Medicina(Kaunas), 2024, 60(7): 1092., articleTitle=null, refAbstract=null), Reference(id=1326652296445931961, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=GUERRA NL, MATAS-GARCIA A, SERRA-GARCIA L,et al. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature[J]. Autoimmun Rev, 2023, 22(8): 103375., articleTitle=null, refAbstract=null), Reference(id=1326652296513040826, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=CHEN CB, WU MY, NG CY, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies[J]. Cancer Manag Res, 2018, 10: 1259-1273., articleTitle=null, refAbstract=null), Reference(id=1326652296580149691, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=AI LY, GAO J, ZHAO SH, et al. Nivolumab-associated DRESS in a genetic susceptible individual[J]. J Immunother Cancer, 2021, 9(10): e002879., articleTitle=null, refAbstract=null), Reference(id=1326652296647258556, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=PARK H, CHOI GS, LEE EM. Successful treatment of imatinib-induced DRESS syndrome using reslizumab without cessation of imatinib: a case report[J]. Case Rep Oncol,2021, 14(3): 1548-1554., articleTitle=null, refAbstract=null), Reference(id=1326652296718561725, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=LI RH, LEI HB, WANG CJ, et al. Clinical features of nivolumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis based on case reports[J]. Front Immunol, 2025, 16: 1563100., articleTitle=null, refAbstract=null), Reference(id=1326652296781476286, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=NIKOLAOU VA, APALLA Z, CARRERA C, et al. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for cancer patients[J]. Br J Dermatol, 2022, 187(6): 962-969., articleTitle=null, refAbstract=null), Reference(id=1326652296844390847, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=SEGHERS S, TEUWEN LA, BEYENS M, et al. Immediate hypersensitivity reactions to antineoplastic agents - a practical guide for the oncologist[J]. Cancer Treat Rev, 2023, 116:102559., articleTitle=null, refAbstract=null), Reference(id=1326652296911499712, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=HIROTSU KE, SCOTT MKD, MARQUEZ C, et al.Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors[J]. J Am Acad Dermatol, 2022, 87(3):651-653., articleTitle=null, refAbstract=null), Reference(id=1326652296986997185, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG SJ, TANG K, WAN G, et al. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study[J]. J Am Acad Dermatol, 2023, 88(5): 1024-1032., articleTitle=null, refAbstract=null), Reference(id=1326652297058300354, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=JUAN-CARPENA G, MARTINEZ BANACLOCHA N,PALAZON CABANES JC, et al. Association of cutaneous immune-related adverse events with overall survival and progression-free survival in oncology patients receiving immune checkpoint inhibitors: a prospective study of 189 patients in a Spanish tertiary care hospital[J]. Acta Derm Venereol, 2025, 105: adv42023, articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1326652289953149313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, xref=null, ext=[AuthorCompanyExt(id=1326652289961537922, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China), AuthorCompanyExt(id=1326652289969926531, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=同济大学附属皮肤病医院风湿免疫科,上海 200443)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.08.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.08.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.08.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.08.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1754755200000, fullTextJson=null, articleText=null, reference=null)
收藏切换
免疫检查点抑制剂皮肤相关不良反应的研究进展
马丽丽 , 林瑞莲 , 陈佳 *
世界临床药物 | 医药专论 2025,46(8): 737-743
收起
收藏切换
世界临床药物 |医药专论 2025 , 46 (8) : 737 -743
免疫检查点抑制剂皮肤相关不良反应的研究进展
全屏
[Author(id=1326652291597316485, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652291672813959, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291597316485, language=EN, stringName=Lili MA, firstName=Lili, middleName=null, lastName=MA, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652291727339912, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291597316485, language=CN, stringName=马丽丽, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=同济大学附属皮肤病医院风湿免疫科,上海 200443, bio={"content":"

马丽丽,住院医师,研究方向:皮肤与性病学、自身免疫性疾病。

"}, bioImg=null, bioContent=

马丽丽,住院医师,研究方向:皮肤与性病学、自身免疫性疾病。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652289953149313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, xref=null, ext=[AuthorCompanyExt(id=1326652289961537922, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China), AuthorCompanyExt(id=1326652289969926531, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=同济大学附属皮肤病医院风湿免疫科,上海 200443)])]), Author(id=1326652291786060170, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652291857363340, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291786060170, language=EN, stringName=Ruilian LIN, firstName=Ruilian, middleName=null, lastName=LIN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652291916083597, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291786060170, language=CN, stringName=林瑞莲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=同济大学附属皮肤病医院风湿免疫科,上海 200443, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652289953149313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, xref=null, ext=[AuthorCompanyExt(id=1326652289961537922, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China), AuthorCompanyExt(id=1326652289969926531, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=同济大学附属皮肤病医院风湿免疫科,上海 200443)])]), Author(id=1326652291974803855, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652292037718417, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291974803855, language=EN, stringName=Jia CHEN, firstName=Jia, middleName=null, lastName=CHEN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652292096438674, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, authorId=1326652291974803855, language=CN, stringName=陈佳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=同济大学附属皮肤病医院风湿免疫科,上海 200443, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652289953149313, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, xref=null, ext=[AuthorCompanyExt(id=1326652289961537922, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China), AuthorCompanyExt(id=1326652289969926531, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652289231729022, companyId=1326652289953149313, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=同济大学附属皮肤病医院风湿免疫科,上海 200443)])])]
马丽丽, 林瑞莲, 陈佳*
作者信息
  • 同济大学附属皮肤病医院风湿免疫科,上海 200443
通讯作者:
陈佳,主任医师,研究方向:皮肤病理、自身免疫性疾病。
作者简介:

马丽丽,住院医师,研究方向:皮肤与性病学、自身免疫性疾病。

Advances of immune checkpiont inhibitor-related cutaneous adverse events
Lili MA, Ruilian LIN, Jia CHEN*
Affiliations
  • Department of Rheumatology, Skin Disease Hospital of Tongji University, Shanghai 200443, China
出版时间: 2025-08-10 doi: 10.13683/j.wph.2025.08.001
文章导航
收藏切换

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)作为恶性肿瘤治疗的突破性药物,通过阻断免疫检查点信号,增强机体对肿瘤细胞的免疫反应从而发挥抗肿瘤作用,但同时也会导致一系列免疫相关不良事件(immune-related adverse events,irAEs),其中皮肤irAEs(cutaneous irAEs,cirAEs)是常见类型之一。该文综述ICIs引起cirAEs的机制、临床表现、治疗及预后,并简要阐述cirAEs与已知药疹的关联,旨在提高医疗专业人员对ICIs相关cirAEs的认识,并为临床治疗提供指导。

免疫相关不良事件  /  皮肤免疫相关不良事件  /  免疫检查点抑制剂

Immune checkpoint inhibitors(ICIs), as revolutionary drugs in cancer therapy, play an anti-tumor role by blocking immune checkpoint signals and enhancing the body's immune response to tumor cells, but also cause a series of immune-related adverse events(irAEs). Cutaneous irAEs(cirAEs) are one of the most common types. This paper reviewed the mechanism, clinical manifestations, treatment and prognosis of cirAEs, and briefly elaborated the relationship between cirAEs and well-known drug eruptions, aiming to increase the awareness of medical professionals about ICIs-related cirAEs and provide guidance for clinical treatment.

immune-related adverse events  /  skin immune-related adverse events  /  immune checkpoint inhibitors
马丽丽, 林瑞莲, 陈佳. 免疫检查点抑制剂皮肤相关不良反应的研究进展. 世界临床药物, 2025 , 46 (8) : 737 -743 . DOI: 10.13683/j.wph.2025.08.001
Lili MA, Ruilian LIN, Jia CHEN. Advances of immune checkpiont inhibitor-related cutaneous adverse events[J]. World Clinical Drug, 2025 , 46 (8) : 737 -743 . DOI: 10.13683/j.wph.2025.08.001

参考文献 引证文献
排序方式:
[1]
BARRON CC, STEFANOVA I, CHA Y, et al. Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review[J]. J Immunother Cancer, 2023, 11(8): e006500.
[2]
GEISLER AN, PHILLIPS GS, BARRIOS DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events[J].J Am Acad Dermatol, 2020, 83(5): 1255-1268.
[3]
WONGVIBULSIN S, PAHALYANTS V, KALINICH M,et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis[J]. J Am Acad Dermatol, 2022, 86(3): 563-572.
[4]
LYUBCHENKO T, LEUNG DYM, GOLEVA E. Why are immune adverse events so common with checkpoint inhibitor therapy?[J]. Ann Allergy Asthma Immunol, 2021, 126(6):608-610.
[5]
PETITPREZ F, DE REYNIES A, KEUNG EZ, et al. B cells are associated with survival and immunotherapy response in sarcoma[J]. Nature, 2020, 577(7791): 556-560.
[6]
KANG JH, BLUESTONE JA, YOUNG A. Predicting and preventing immune checkpoint inhibitor toxicity: targeting cytokines[J]. Trends Immunol, 2021, 42(4): 293-311.
[7]
CHAM J, ZHANG L, KWEK S, et al. Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies[J].J Immunother Cancer, 2020, 8(1): e000368.
[8]
TENG YS, YU S. Molecular mechanisms of cutaneous immune-related adverse events(irAEs) induced by immune checkpoint inhibitors[J]. Curr Oncol, 2023, 30(7): 6805-6819.
[9]
NISHIMURA K, KONISHI T, OCHI T, et al. CD21lo B Cells could be a potential predictor of immune-related adverse events in renal cell carcinoma[J]. J Pers Med, 2022, 12(6):888.
[10]
GU SL, MAIER T, MOY AP, et al. IL12/23 blockade with ustekinumab as a treatment for immune-related cutaneous adverse events[J]. Pharmaceuticals(Basel), 2023, 16(11):1548.
[11]
SHIPMAN WD, SINGH K, COHEN JM, et al. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin(IL)-4 and IL-13 expression and responds to dupilumab treatment[J]. Br J Dermatol, 2023,189(3): 339-341.
[12]
OKIYAMA N, TANAKA R. Immune-related adverse events in various organs caused by immune checkpoint inhibitors[J].Allergol Int, 2022, 71(2): 169-178.
[13]
YIN Q, WU L, HAN L, et al. Immune-related adverse events of immune checkpoint inhibitors: a review[J]. Front Immunol, 2023, 14: 1167975.
[14]
STARACE M, RAPPARINI L, CEDIRIAN S, et al.Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience[J].Support Care Cancer, 2024, 32(3): 200.
[15]
ALMODOVAR CRUZ GE, KAUNITZ G, STEIN JE, et al.Immune cell subsets in interface cutaneous immune-related adverse events associated with anti-PD-1 therapy resemble acute graft versus host disease more than lichen planus[J]. J Cutan Pathol, 2022, 49(8): 701-708.
[16]
BROWN AM, MASTERSON W, LO J, et al. Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: a review[J]. Dermatitis, 2023,34(3): 201-208.
[17]
MUNTYANU A, NETCHIPOROUK E, GERSTEIN W, et al. Cutaneous immune-related adverse events(irAEs) to Immune checkpoint inhibitors: a dermatology perspective on management[J]. J Cutan Med Surg, 2021, 25(1): 59-76.
[18]
SUN XJ, MEI XL, LIU Y. Exacerbation of psoriasis induced by nivolumab in a patient with stage Ⅲc gastric adenocarcinoma: a case report and literature review[J]. J Transl Autoimmun, 2023, 6: 100193.
[19]
POPA LG, GIURCANEANU C, PORTELLI MG, et al.Perspectives on psoriasiform adverse events from immune checkpoint inhibitors: lessons learned from our practice[J].Medicina(Kaunas), 2024, 60(3): 373.
[20]
PACH JJ, MBONU N, BHULLAR S, et al. Immune checkpoint inhibitor-induced psoriasis: diagnosis,management, and a review of cases[J]. Dermatol Clin, 2024,42(3): 481-493.
[21]
Schaberg KB, Novoa RA, Wakelee HA, et al.Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy[J]. J Cutan Pathol, 2016, 43(4): 339-346.
[22]
TETZLAFF MT, NAGARAJAN P, CHON S, et al. Lichenoid dermatologic toxicity from immune checkpoint blockade therapy: a detailed examination of the clinicopathologic features[J]. Am J Dermatopathol, 2017, 39(2): 121-129.
[23]
FIXSEN E, PATEL J, SELIM MA, et al. Resolution of pembrolizumab-associated steroid-refractory lichenoid dermatitis with cyclosporine[J]. Oncologist, 2019, 24(3):e103-e105.
[24]
CARBONE ML, CAPONE A, GUERCIO M, et al. Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy[J]. Front Immunol, 2023, 14: 1197630.
[25]
RAO H, GUO Z, WEN XJ, et al. Case report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data[J]. Front Oncol,2023, 12: 1099108.
[26]
LOMMERTS JE, BEKKENK MW, LUITEN RM. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion[J]. Expert Opin Drug Saf, 2021,20(8): 883-888.
[27]
BHARDWAJ M, CHIU MN, PILKHWAL SAH S. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance[J].Cutan Ocul Toxicol, 2022, 41(1): 73-90.
[28]
TAN HW, CHEN XB, CHEN Y, et al. Immune checkpoint inhibitor-associated bullous pemphigoid: A retrospective and real-world study based on the United States Food and Drug Administration adverse event reporting system[J]. J Dermatol, 2025, 52(2): 309-316.
[29]
NAIDOO J, SCHINDLER K, QUERFELD C, et al.Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1[J]. Cancer Immunol Res, 2016, 4(5): 383-389.
[30]
ASDOURIAN MS, SHAH N, JACOBY TV, et al. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review[J]. J Am Med Assoc Dermatol, 2022, 158(8): 933-941.
[31]
TERRIER B, HUMBERT S, PRETA LH, et al. Risk of scleroderma according to the type of immune checkpoint inhibitors[J]. Autoimmun Rev, 2020, 19(8): 102596.
[32]
PAI HL, LIU CY, YEH MH. Scleroderma-like lesions in a patient undergoing combined pembrolizumab and routine chemotherapy: a case report and literature review[J].Medicina(Kaunas), 2024, 60(7): 1092.
[33]
GUERRA NL, MATAS-GARCIA A, SERRA-GARCIA L,et al. Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature[J]. Autoimmun Rev, 2023, 22(8): 103375.
[34]
CHEN CB, WU MY, NG CY, et al. Severe cutaneous adverse reactions induced by targeted anticancer therapies and immunotherapies[J]. Cancer Manag Res, 2018, 10: 1259-1273.
[35]
AI LY, GAO J, ZHAO SH, et al. Nivolumab-associated DRESS in a genetic susceptible individual[J]. J Immunother Cancer, 2021, 9(10): e002879.
[36]
PARK H, CHOI GS, LEE EM. Successful treatment of imatinib-induced DRESS syndrome using reslizumab without cessation of imatinib: a case report[J]. Case Rep Oncol,2021, 14(3): 1548-1554.
[37]
LI RH, LEI HB, WANG CJ, et al. Clinical features of nivolumab-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: retrospective analysis based on case reports[J]. Front Immunol, 2025, 16: 1563100.
[38]
NIKOLAOU VA, APALLA Z, CARRERA C, et al. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for cancer patients[J]. Br J Dermatol, 2022, 187(6): 962-969.
[39]
SEGHERS S, TEUWEN LA, BEYENS M, et al. Immediate hypersensitivity reactions to antineoplastic agents - a practical guide for the oncologist[J]. Cancer Treat Rev, 2023, 116:102559.
[40]
HIROTSU KE, SCOTT MKD, MARQUEZ C, et al.Histologic subtype of cutaneous immune-related adverse events predicts overall survival in patients receiving immune checkpoint inhibitors[J]. J Am Acad Dermatol, 2022, 87(3):651-653.
[41]
ZHANG SJ, TANG K, WAN G, et al. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study[J]. J Am Acad Dermatol, 2023, 88(5): 1024-1032.
[42]
JUAN-CARPENA G, MARTINEZ BANACLOCHA N,PALAZON CABANES JC, et al. Association of cutaneous immune-related adverse events with overall survival and progression-free survival in oncology patients receiving immune checkpoint inhibitors: a prospective study of 189 patients in a Spanish tertiary care hospital[J]. Acta Derm Venereol, 2025, 105: adv42023
2025年第46卷第8期
55
12
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.08.001
  • 接收时间:2025-04-18
  • 首发时间:2026-11-09
  • 出版时间:2025-08-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2025-04-18
基金
作者信息
    同济大学附属皮肤病医院风湿免疫科,上海 200443

通讯作者:

陈佳,主任医师,研究方向:皮肤病理、自身免疫性疾病。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.08.001
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏